Domestic oral treatment treatment of new crown pneumonia, Azf, was approved for about 5 days to clear the virus can be cleared

On July 25, the State Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the Drug Management Law in accordance with the relevant provisions of the Drug Management Law. Symptom registration application.

This product is the treatment of oral small molecular virus pneumonia for oral small molecular virus pneumonia in my country. On July 20, 2021, the State Drug Administration has attached conditions to approve this product and other reverse-translitease inhibitors to treat adult HIV-1 infection patients with high virus load. This is an attachment to approve new indications for the treatment of adult patients with COVID-19) for the treatment of ordinary new type of coronary virus pneumonia. Patients should be used strictly under the guidance of the doctor.

The State Drug Administration requires listing permit holders to continue to carry out relevant research work, complete the requirements for qualified conditions within a time limit, and submit subsequent research results in a timely manner.

According to the WeChat public account of Henan Real Biotechnology Co., Ltd., "Real Biotechnology", Azf has the activity of inhibiting the new coronary virus, and the virus clearance time is about 5 days.

Professor Chang Junbiao, deputy secretary and vice president of Zhengzhou University, said: "Azfdin as a nucleoside analog of nucleosides in RNA -dependent RNA polymerase (RDRP) New coronary virus RDRP, which inhibits virus replication, has strong drugs. "

Academician Jiang Jiandong of the Academy of Pharmaceuticals of the Chinese Academy of Medical Sciences said: "Azf will have obvious anti -new coronary virus effects and is effective for patients with clinical severe illnesses. Different biological characteristics. "

Reporter: Xing Can

- END -